RUNX1 Antikörper

Produktnummer ABIN2665355

Dieses Anti-RUNX1-Antikörper ist ein Maus Monoklonal-Antikörper zur Detektion von RUNX1 in FACS. Geeignet für Human.

Kurzübersicht für RUNX1 Antikörper (ABIN2665355)

Target: RUNX1 (Runt-Related Transcription Factor 1 (RUNX1))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser RUNX1 Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS)

Klon: 1C5B16

Produktdetails anti-RUNX1 Antikörper

Kreuzreaktivität: Maus, Human

Kreuzreaktivität (Details): Human

Aufreinigung: The antibody was purified by affinity chromatography.

Isotyp: IgG2a kappa

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 0.5 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Informationen zur Lagerung: The antibody solution should be stored undiluted between 2°C and 8°C.

Details zu RUNX1

Target: RUNX1 (Runt-Related Transcription Factor 1 (RUNX1))

Andere Bezeichnung: RUNX1

Hintergrund: RUNX1 belongs to the runt domain family of transcription factors and regulates target gene expression through forming a heterodimeric DNA-binding complex with CBFB. RUNX1 was first identified as a RUNX1-ETO fusion protein in acute myeloid leukaemia (AML) and is frequently mutated in AML and myelodysplastic syndrome due to chromosomal translocation. RUNX1-deficient mice fail to generate hematopoietic stem cells. RUNX1 regulates CD4 gene transcription during multiple stages of T cell development and represses the CD4 gene in CD4-CD8- (double negative) T cells. RUNX1 is also required for the differentiation of CD8+, Th17, and regulatory T cells. Impaired differentiation of megakaryocytes and decreased circulating platelet count was observed in the absence of RUNX1. These findings revealed that RUNX1 acts as a tumor suppressor for myeloid leukemia and is crucial for the development and terminal differentiation of several blood cell lineages.